Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bavarian Nordic A/S - ADR - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
BVNRY
Over the counter
2836
https://www.bavarian-nordic.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bavarian Nordic A/S - ADR
Bavarian Nordic A/S – Notice Convening Annual General Meeting
- Mar 21st, 2024 11:00 am
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland
- Mar 13th, 2024 12:29 pm
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
- Mar 12th, 2024 4:30 pm
Bavarian Nordic Publishes Annual Report 2023
- Mar 6th, 2024 6:38 am
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines Agency
- Feb 23rd, 2024 6:35 am
Bavarian Nordic terminates cancer vaccine work
- Feb 21st, 2024 12:05 pm
Bavarian Nordic delivered record financial results in 2023
- Feb 21st, 2024 7:13 am
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
- Dec 13th, 2023 9:33 pm
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Nov 30th, 2023 9:47 am
Bavarian Nordic to hold Capital Markets Days in February 2024
- Nov 22nd, 2023 5:00 pm
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023
- Nov 16th, 2023 6:37 am
UPDATE 2-US CDC recommends routine use of Bavarian Nordic mpox vaccine for adults at risk
- Oct 25th, 2023 6:25 pm
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk
- Oct 25th, 2023 6:03 pm
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
- Sep 13th, 2023 9:33 am
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine Program
- Aug 31st, 2023 3:08 pm
Bavarian Nordic Announces First Half 2023 Results
- Aug 23rd, 2023 5:35 am
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
- Aug 6th, 2023 7:54 pm
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
- Aug 3rd, 2023 5:28 am
UPDATE 1-Bavarian Nordic ends RSV vaccine programme after poor trial results
- Jul 22nd, 2023 5:32 pm
Bavarian Nordic Provides Update on RSV Vaccine Program
- Jul 22nd, 2023 4:42 pm
Scroll